Publicaciones en colaboración con investigadores/as de University of Paris-Sorbonne (20)

2024

  1. Outpatient management of cancer-associated pulmonary embolism: A post-hoc analysis from the HOME-PE trial

    Thrombosis Research, Vol. 235, pp. 79-87

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Pulmonary Embolism and Chronic Obstructive Pulmonary Disease

    Seminars in Thrombosis and Hemostasis, Vol. 49, Núm. 8, pp. 809-815

2022

  1. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

    The Lancet Oncology, Vol. 23, Núm. 7, pp. e334-e347

  2. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

    Research and Practice in Thrombosis and Haemostasis, Vol. 6, Núm. 4

  3. Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial

    Thrombosis and Haemostasis, Vol. 122, Núm. 5, pp. 857-866

2021

  1. Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: The HOME-PE randomized trial

    European Heart Journal, Vol. 42, Núm. 33, pp. 3146-3157

2020

  1. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS)

    European Heart Journal, Vol. 41, Núm. 4, pp. 543-603

2019

  1. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

    European Respiratory Journal, Vol. 54, Núm. 3

  2. Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial

    Clinical Research in Cardiology, Vol. 108, Núm. 7, pp. 772-778

2018

  1. Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism

    Thrombosis Research, Vol. 163, pp. 128-131

2017

  1. Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study

    Thrombosis and Haemostasis, Vol. 117, Núm. 12, pp. 2425-2434

  2. Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism

    Journal of the American College of Cardiology, Vol. 69, Núm. 12, pp. 1536-1544

  3. Prognostic value of right ventricular dilatation in patients with low-risk pulmonary embolism

    European Respiratory Journal, Vol. 50, Núm. 6

  4. Rivaroxaban with or without aspirin in stable cardiovascular disease

    New England Journal of Medicine, Vol. 377, Núm. 14, pp. 1319-1330

2015

  1. Risk assessment and management of high and intermediate risk pulmonary embolism

    Presse Medicale

  2. Validation of a model for identification of patients at intermediate to high risk for complications associated with acute symptomatic pulmonary embolism

    Chest, Vol. 148, Núm. 1, pp. 211-218

2014

  1. Fibrinolysis for patients with intermediate-risk pulmonary embolism

    New England Journal of Medicine, Vol. 370, Núm. 15, pp. 1402-1411

  2. Identification of intermediate-risk patients with acute symptomatic pulmonary embolism

    European Respiratory Journal, Vol. 44, Núm. 3, pp. 694-703

2012

  1. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: Rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial.

    American Heart Journal, Vol. 163, Núm. 1